X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (540) 540
hematology (369) 369
male (333) 333
middle aged (328) 328
female (326) 326
adult (306) 306
index medicus (254) 254
aged (253) 253
oncology (182) 182
treatment outcome (169) 169
adolescent (127) 127
hemic and lymphatic diseases (123) 123
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (123) 123
imatinib mesylate (120) 120
chronic myelogenous leukemia (118) 118
antineoplastic agents - therapeutic use (115) 115
chronic myeloid leukemia (111) 111
prognosis (98) 98
aged, 80 and over (94) 94
benzamides (94) 94
antineoplastic combined chemotherapy protocols - therapeutic use (91) 91
imatinib (89) 89
pyrimidines - therapeutic use (89) 89
protein kinase inhibitors - therapeutic use (79) 79
piperazines - therapeutic use (78) 78
young adult (72) 72
leukemia, myelogenous, chronic, bcr-abl positive - genetics (70) 70
leukemia (69) 69
therapy (68) 68
chemotherapy (67) 67
disease-free survival (65) 65
remission induction (63) 63
dasatinib (60) 60
retrospective studies (59) 59
follow-up studies (58) 58
survival (58) 58
fusion proteins, bcr-abl - genetics (57) 57
time factors (56) 56
cancer (55) 55
chronic myeloid-leukemia (52) 52
care and treatment (51) 51
survival analysis (50) 50
abridged index medicus (49) 49
bcr-abl (49) 49
hematology, oncology and palliative medicine (47) 47
pyrimidines - administration & dosage (46) 46
survival rate (45) 45
transplantation (43) 43
tyrosine kinase inhibitors (43) 43
rituximab (42) 42
analysis (41) 41
recurrence (41) 41
nilotinib (40) 40
follow-up (39) 39
resistance (39) 39
antineoplastic agents - administration & dosage (36) 36
piperazines - administration & dosage (35) 35
mutation (34) 34
antineoplastic agents (33) 33
cml (33) 33
drug therapy (33) 33
antineoplastic agents - adverse effects (32) 32
antineoplastic combined chemotherapy protocols - administration & dosage (32) 32
antineoplastic combined chemotherapy protocols - adverse effects (32) 32
drug resistance, neoplasm (32) 32
risk factors (32) 32
interferon-alpha (31) 31
leukemia, myeloid, chronic-phase - drug therapy (31) 31
protein-tyrosine kinases - antagonists & inhibitors (31) 31
pyrimidines - adverse effects (30) 30
research (30) 30
tyrosine (30) 30
chronic-phase (29) 29
combined modality therapy (29) 29
cytarabine - administration & dosage (29) 29
leukemia, myelogenous, chronic, bcr-abl positive - mortality (29) 29
multiple myeloma (29) 29
acute myeloid-leukemia (28) 28
cells (28) 28
medicine & public health (28) 28
neoplasms (28) 28
leukemia, myelogenous, chronic, bcr-abl positive - therapy (27) 27
non-hodgkins-lymphoma (27) 27
prospective studies (27) 27
recommendations (27) 27
risk (27) 27
transplantation, homologous (27) 27
cyclophosphamide - administration & dosage (26) 26
genetic aspects (26) 26
stem-cell transplantation (26) 26
tyrosine kinase inhibitor (26) 26
bone-marrow transplantation (25) 25
expression (25) 25
vincristine - administration & dosage (25) 25
bone marrow transplantation (24) 24
dose-response relationship, drug (24) 24
philadelphia chromosome (24) 24
reverse transcriptase polymerase chain reaction (24) 24
transplantation, autologous (24) 24
antimitotic agents (23) 23
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9758, pp. 2075 - 2085
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 02/2017, Volume 14, Issue 3, pp. 141 - 154
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2017, Volume 376, Issue 10, pp. 917 - 927
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 612 - 621
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2009, Volume 27, Issue 35, pp. 6041 - 6051
Journal Article